PGP and ovarian cancer: The potential use of calcium channel blocking drugs in cancer therapy to revert MDR [26] and the affinity to P-gp observed for apiole by molecular docking prompted the antiproliferative study associating apiole and two chemotherapeutic drugs frequently used in the clinic (doxorubicin and vincristine) in two ovarian cancer cell lines (NCI/ADR-RES, which expresses the phenotype of resistance to multiple drugs, characterized by the high expression of P-gp [27]; and OVCAR-3).